A groundbreaking vaccine designed to combat Alzheimer’s disease is set to begin human trials in Adelaide, Australia next week. This marks a significant advancement in the fight against dementia. Developed by Vaxine Pty Ltd in collaboration with the Institute for Molecular Medicine, the vaccine aims to stimulate the immune system to produce antibodies that target...
Dying Patients Fear Pioneering Trial will be forced to shut Down The Daily Telegraph has published an article highlighting a critical issue facing a pioneering cancer vaccine trial. The trial, which offers hope to terminally ill patients, is under threat of being shut down due to decisions made by the government health network. This development...
The COVID-19 vaccine developed by Vaxine has now received a marketing authorisation from the Iranian FDA for children aged 5 years and above. This follows a successful clinical trial where the vaccine was tested in children between 5 and 18 years of age and was shown to be safe and effective in inducing neutralizing antibodies...
ZAA-accredited zoos welcome the opportunity to add an extra layer of protection to the health of their animals with a veterinary vaccine for COVID-19 being made available for zoo animals. Safety was a key consideration in selecting this vaccine option for zoo animals. It has already been shown to be safe and effective in multiple...
Vaxine is pleased to see its latest Covid-19 vaccine Phase 2 trial results complete peer review and be published in the journal “Clinical Microbiology and Infection”, the official journal of the European Society of Clinical Microbiology and Infectious Diseases. This paper investigates the immunogenicity ad efficacy of Vaxine’s vaccine composed of a recombinant prefusion-stabilized SARS-CoV-2...